Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.45 |
| ▸ | NTMT1 | Q9BV86 | 3/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007009 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3NTMT1UGCG | |
| SCHEMBL16007049 | 0.88 | CHRM3 (0.51) | CHRM2CHRM1CHRM3NTMT1UGCG | |
| SCHEMBL30745971 | 0.88 | CHRM3 (0.51) | CHRM2CHRM1CHRM3NTMT1UGCG | |
| SCHEMBL16007046 | 0.88 | CHRM3 (0.51) | CHRM2CHRM1CHRM3NTMT1UGCG | |
| SCHEMBL16007024 | 0.85 | NTMT1 (0.51) | CHRM2CHRM1CHRM3NTMT1CHRNA7 | |
| SCHEMBL29356569 | 0.82 | CHRM3 (0.55) | CHRM2CHRM1CHRM3NTMT1UGCG | |
| SCHEMBL16007035 | 0.81 | CHRNA7 (0.46) | CHRM2CHRM1CHRM3NTMT1CHRNA7 | |
| SCHEMBL16007179 | 0.81 | CHRNA7 (0.59) | CHRM2CHRM1CHRM3CHRNA7BCHE | |
| SCHEMBL16007093 | 0.81 | CHRM3 (0.42) | CHRM2CHRM1CHRM3NTMT1UGCG | |
| SCHEMBL31613798 | 0.80 | CHRM3 (0.52) | CHRM2CHRM1CHRM3NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-3673906-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2020-02-13 | — | — | US | disclosed |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-9139580-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9126993-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048266-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM2 4876/4885CHRM1 4878/4885CHRM3 4870/4885 |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM2 4875/4885CHRM1 4879/4885CHRM3 4870/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM2 4875/4885CHRM1 4879/4885CHRM3 4870/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM2 4875/4885CHRM1 4879/4885CHRM3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.